Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Radioactive drug shows promise for Hard-to-Treat blood cancers

NCT ID NCT02952508

First seen Mar 27, 2026 · Last updated May 24, 2026 · Updated 8 times

Summary

This study tests an experimental radioactive drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have come back or not responded to standard treatments. The drug is designed to target and kill cancer cells. The study has two parts: one looks at how well the drug works for various B-cell cancers, and the other focuses specifically on Waldenstrom macroglobulinemia. About 120 adults aged 18 and older are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Cellectar Biosciences

    Atlanta, Georgia, 30332, United States

  • Cellectar Biosciences

    Bethesda, Maryland, 20817, United States

  • Cellectar Biosciences

    North Bergen, New Jersey, 07047, United States

  • Cellectar Biosciences

    Canton, Ohio, 44718, United States

  • Cellectar Biosciences

    Greenville, South Carolina, 29605, United States

  • Cellectar Biosciences

    Adelaide, South Australia, 5000, Australia

  • Cellectar Biosciences

    Salvador, Estado de Bahia, 40050-410, Brazil

  • Cellectar Biosciences

    Curitiba, Paraná, 80810-050, Brazil

  • Cellectar Biosciences

    Porto Alegre, RioGrande Do Sul, 90035-903, Brazil

  • Cellectar Biosciences

    Blumenau, Santa Catarina, 89010-340, Brazil

  • Cellectar Biosciences

    Helsinki, 00029, Finland

  • Cellectar Biosciences

    Pessac, 33600, France

  • Cellectar Biosciences

    Poitiers, 86021, France

  • Cellectar Biosciences

    Barcelona, 08036, Spain

  • Cellectar Biosciences

    Madrid, 28027, Spain

  • Cellectar Biosciences

    Madrid, 28040, Spain

  • Cellectar Biosciences

    Salamanca, 37007, Spain

  • Cellectar Biosciences

    Ankara, 06620, Turkey (Türkiye)

  • Cellectar Biosciences

    Bornova, 35100, Turkey (Türkiye)

  • Cellectar Biosciences

    Istanbul, 34093, Turkey (Türkiye)

  • Cellectar Biosciences Site

    Charleston, South Carolina, 29425, United States

  • Cellectar Biosciences Site

    Hradec Králové, 500 05, Czechia

  • Cellectar Biosciences Site

    Rio, Greece

  • Cellectar Biosciences Site

    Jerusalem, Israel

  • Cellectar Biosciences site

    Los Angeles, California, 90095, United States

  • Cellectar Biosciences site

    Redlands, California, 92373, United States

  • Cellectar Biosciences site

    Washington D.C., District of Columbia, 20007, United States

  • Cellectar Biosciences site

    Jacksonville, Florida, 32224, United States

  • Cellectar Biosciences site

    Miami, Florida, 33165, United States

  • Cellectar Biosciences site

    Tampa, Florida, 33612, United States

  • Cellectar Biosciences site

    Maywood, Illinois, 60153, United States

  • Cellectar Biosciences site

    Warrenville, Illinois, 60555, United States

  • Cellectar Biosciences site

    Westwood, Kansas, 66205, United States

  • Cellectar Biosciences site

    New Orleans, Louisiana, 70121, United States

  • Cellectar Biosciences site

    Baltimore, Maryland, 21287, United States

  • Cellectar Biosciences site

    Boston, Massachusetts, 02215, United States

  • Cellectar Biosciences site

    Buffalo, New York, 14263, United States

  • Cellectar Biosciences site

    New York, New York, 10065, United States

  • Cellectar Biosciences site

    Rochester, New York, 14642, United States

  • Cellectar Biosciences site

    Durham, North Carolina, 27705, United States

  • Cellectar Biosciences site

    Cincinnati, Ohio, 45219, United States

  • Cellectar Biosciences site

    Knoxville, Tennessee, 37920, United States

  • Cellectar Biosciences site

    Dallas, Texas, 75246, United States

  • Cellectar Biosciences site

    Dallas, Texas, 75390, United States

  • Cellectar Biosciences site

    Houston, Texas, 77030, United States

  • Cellectar Biosciences site

    Seattle, Washington, 98109, United States

  • Cellectar Biosciences site

    Madison, Wisconsin, 53792, United States

  • Cellectar Biosciences site

    Concord, New South Wales, 2139, Australia

  • Cellectar Biosciences site

    Athens, 115 28, Greece

  • Cellectar Biosciences site

    Barcelona, 08908, Spain

  • Cellectar Biosciences site

    Zaragoza, 50009, Spain

  • Cellectar Biosciences site

    London, NW1 2PG, United Kingdom

Conditions

Explore the condition pages connected to this study.